Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M

Những quyển sách tương tự

• Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
  Bằng: Oxnard, Geoffrey R., et al.
  Được phát hành: (2016)
• EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1(st) generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples
  Bằng: Rangachari, Deepa, et al.
  Được phát hành: (2019)
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
  Bằng: Cross, Darren A. E., et al.
  Được phát hành: (2014)
• Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models
  Bằng: Eberlein, Catherine A., et al.
  Được phát hành: (2015)
• Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
  Bằng: Wang, Nannan, et al.
  Được phát hành: (2019)